LVRNA012 / AIM Vaccine - LARVOL DELTA

Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial. (PubMed, Front Immunol) - P=N/A | "This is a single-center, randomized, double-blind, placebo-controlled phase 3 clinical trial enrolling healthy adult participants (≥18 years) who had completed two or three doses of inactivated COVID-19 vaccines at least 6 months before, in Bengbu, Anhui province, China. The LVRNA012 mRNA vaccine is immunogenic, and shows robust efficacy in preventing COVID-19 during the omicron-predominate period. ClinicalTrials.gov, identifier NCT05745545."

Clinical • Journal • P3 data • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over (clinicaltrials.gov) - P=N/A | N=3200 | Recruiting | Sponsor: AIM Vaccine Co., Ltd.

New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People (clinicaltrials.gov) - P=N/A | N=350 | Not yet recruiting | Sponsor: AIM Vaccine Co., Ltd. | Initiation date: Nov 2022 ➔ Feb 2023 | Trial primary completion date: Jan 2023 ➔ May 2023

Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL13 • IL2 • IL4

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China (clinicaltrials.gov) - P=N/A | N=54 | Active, not recruiting | Sponsor: AIM Vaccine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China (clinicaltrials.gov) - P=N/A | N=54 | Recruiting | Sponsor: AIM Vaccine Co., Ltd.

New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People (clinicaltrials.gov) - P=N/A | N=350 | Not yet recruiting | Sponsor: AIM Vaccine Co., Ltd.

New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL13 • IL2 • IL4